Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
暂无分享,去创建一个
A. Jakubowska | J. Lubiński | S. Narod | P. Sun | C. Cybulski | D. Wokołorczyk | W. Kluźniak | M. Akbari | T. Byrski | T. Huzarski | J. Gronwald | T. Dębniak | B. Górski | V. Sopik | M. Szwiec | A. Kashyap
[1] A. Jakubowska,et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland , 2015, Clinical genetics.
[2] Nazneen Rahman,et al. Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.
[3] T. Dörk,et al. Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe , 2014, Familial Cancer.
[4] Tina Pesaran,et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.
[5] P. Dundr,et al. The PALB2 Gene Is a Strong Candidate for Clinical Testing in BRCA1- and BRCA2-Negative Hereditary Breast Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[6] Daniel J. Park,et al. Tumour morphology predicts PALB2 germline mutation status , 2013, British Journal of Cancer.
[7] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[8] T. Walsh,et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.
[9] Daniel J. Park,et al. A PALB2 mutation associated with high risk of breast cancer , 2010, Breast Cancer Research.
[10] Bing Xia,et al. PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.
[11] S. Hammes,et al. Just when you thought it was safe to go into the membrane: the growing complexities of extra-nuclear progesterone signaling , 2010, Breast Cancer Research.
[12] F. Sera,et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy , 2010, Familial Cancer.
[13] M. Dąbrowska,et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.
[14] H. Nevanlinna,et al. The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2009, Clinical Cancer Research.
[15] P. Pharoah,et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? , 2009, British Journal of Cancer.
[16] J. Hopper,et al. Penetrance Analysis of the PALB2 c.1592delT Founder Mutation , 2008, Clinical Cancer Research.
[17] W. Foulkes,et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.
[18] Katri Pylkäs,et al. A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.
[19] S. Seal,et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.
[20] J. Lubiński,et al. Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland , 2006, Hereditary Cancer in Clinical Practice.
[21] A. Jakubowska,et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. , 2000, American journal of human genetics.
[22] Karla Bowles,et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.